<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sorafenib: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sorafenib: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sorafenib: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11575" href="/d/html/11575.html" rel="external">see "Sorafenib: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F2307883"><span class="drugH1">Brand Names: US</span>
<ul>
<li>NexAVAR</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868745"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>NexAVAR</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F2307887"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Tyrosine Kinase Inhibitor;</li>
<li>
                        Antineoplastic Agent, Vascular Endothelial Growth Factor (VEGF) Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F2322555"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Temporarily withhold sorafenib for at least 10 days prior to elective surgery; do not administer sorafenib for at least 2 weeks following major surgery and until adequate wound healing.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b12c5cbe-89c2-4211-ab16-15d280500cad">Hepatocellular carcinoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatocellular carcinoma: Oral:</b> 400 mg twice daily; continue until no longer clinically benefiting or until unacceptable toxicity occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18650514']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18650514'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label dosing:</i> A large, retrospective analysis in patients with HCC determined that a reduced initial dose (&lt;800 mg/day) was associated with a reduced pill burden, reduced cost, and a trend toward reduced discontinuation rates while not associated with inferior overall survival rates. Most patients had Child-Pugh class A or B impairment; the average sorafenib starting dose was 367 mg/day; doses were escalated within 2 months of initiation in less than half of the patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28872925']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28872925'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="045bd6ae-3edd-419a-aa75-2a643fc49694">Renal cell carcinoma, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal cell carcinoma, advanced:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Sorafenib is mainly utilized as later-line therapy for advanced renal cell carcinoma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Atkins.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Atkins.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 400 mg twice daily; continue until disease progression or until unacceptable toxicity occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17215530','lexi-content-ref-19451442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17215530','lexi-content-ref-19451442'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2cafc4b2-dec7-4a86-ba46-38c810aeb12a">Thyroid carcinoma, differentiated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid carcinoma, differentiated:</b>
<b>Oral:</b> 400 mg twice daily; continue until disease progression or until unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24768112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24768112'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3cf4c1db-6eab-47af-82ef-e1b41b164f5f">Angiosarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Angiosarcoma (off-label use):</b>
<b>Oral:</b> 400 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19451436']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19451436'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d33cefa4-a759-4f8b-aef5-af5f750cd64f">Gastrointestinal stromal tumor</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastrointestinal stromal tumor (off-label use):</b>
<b>Oral:</b> 400 mg twice daily until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kindler.2018','lexi-content-ref-23140824','lexi-content-ref-22270258']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kindler.2018','lexi-content-ref-23140824','lexi-content-ref-22270258'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990466"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Manufacturer’s labeling: No dosage adjustment is necessary for mild, moderate, or severe impairment (not dependent on dialysis); has not been studied in dialysis patients.</p>
<p style="text-indent:-2em;margin-left:2em;">A pharmacokinetic study evaluated sorafenib dosing to determine an initial tolerable dose in patients with varying degrees of renal dysfunction. The following empiric starting doses were identified based on patient tolerance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19255312']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19255312'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 40 to 59 mL/minute: 400 mg twice daily</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 20 to 39 mL/minute: 200 mg twice daily</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;20 mL/minute: Data inadequate to define dose</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis (any CrCl): 200 mg once daily</p></div>
<div class="block doha drugH1Div" id="F50987702"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment at baseline:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Manufacturer's labeling:</p>
<p style="text-indent:-2em;margin-left:6em;">Mild to moderate (Child-Pugh class A and B) impairment: No dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:4em;">A pharmacokinetic study evaluated sorafenib dosing to determine an initial tolerable dose in patients with varying degrees of hepatic dysfunction. The following empiric starting doses were identified based on patient tolerance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19255312']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19255312'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Mild hepatic dysfunction (bilirubin &gt;1 to ≤1.5 times ULN and/or AST &gt;ULN): 400 mg twice daily</p>
<p style="text-indent:-2em;margin-left:6em;">Moderate hepatic dysfunction (bilirubin &gt;1.5 to ≤3 times ULN; any AST): 200 mg twice daily</p>
<p style="text-indent:-2em;margin-left:6em;">Severe hepatic dysfunction:</p>
<p style="text-indent:-2em;margin-left:8em;">Albumin &lt;2.5 g/dL (any bilirubin and any AST): 200 mg once daily</p>
<p style="text-indent:-2em;margin-left:8em;">Bilirubin &gt;3 to 10 x ULN (any AST): A dose of 200 mg every 3 days was <b>not</b> tolerated, therefore no dosage was identified in this pharmacokinetic study for patients meeting these parameters.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Drug-induced liver injury during treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">ALT elevation, grade 3 or higher (in the absence of another cause): Permanently discontinue sorafenib.</p>
<p style="text-indent:-2em;margin-left:4em;">ALT, AST &gt;3 times ULN with bilirubin &gt;2 times ULN (in the absence of another cause): Permanently discontinue sorafenib.</p>
<p style="text-indent:-2em;margin-left:4em;">Alkaline phosphatase increase (any grade) in the absence of known bone pathology and bilirubin increase (grade 2 or higher): Permanently discontinue sorafenib.</p>
<p style="text-indent:-2em;margin-left:4em;">INR ≥1.5 considered to be due to drug-induced liver injury: Permanently discontinue sorafenib.</p>
<p style="text-indent:-2em;margin-left:4em;">Ascites and/or encephalopathy (in the absence of underlying cirrhosis or other organ failure) considered to be due to drug-induced liver injury: Permanently discontinue sorafenib.</p></div>
<div class="block dot drugH1Div" id="F2322558"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Recommended Sorafenib Dose Reduction Levels for Adverse Reactions</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Dose reduction</p></th>
<th align="center">
<p style="text-indent:0em;">Hepatocellular carcinoma and renal cell carcinoma</p></th>
<th align="center">
<p style="text-indent:0em;">Differentiated thyroid carcinoma</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">Usual (initial) dose</p></td>
<td align="center">
<p style="text-indent:0em;">400 mg twice daily</p></td>
<td align="center">
<p style="text-indent:0em;">400 mg twice daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">First dose reduction</p></td>
<td align="center">
<p style="text-indent:0em;">400 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;">400 mg (morning) and 200 mg (evening) ~12 hours apart <b>or</b> 200 mg (morning) and 400 mg (evening) ~12 hours apart</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Second dose reduction</p></td>
<td align="center">
<p style="text-indent:0em;">200 mg once daily <b>or</b> 400 mg every other day</p></td>
<td align="center">
<p style="text-indent:0em;">200 mg twice daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Third dose reduction</p></td>
<td align="center">
<p style="text-indent:0em;">None</p></td>
<td align="center">
<p style="text-indent:0em;">200 mg once daily</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Adverse Reactions Requiring Sorafenib Dosage Adjustment</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Adverse reaction</p></th>
<th align="center">
<p style="text-indent:0em;">Severity</p></th>
<th align="center">
<p style="text-indent:0em;">Sorafenib dosage modification</p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>If sorafenib is discontinued, a drop in BP is expected and antihypertensive therapy should be reduced and/or interrupted as clinically appropriate (ESC [Lyon 2022]).</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> ASCO (Armenian 2017); ESC (Lyon 2022).</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">Cardiac ischemia and/or infarction</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 2 or higher</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue sorafenib.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Heart failure</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;">Interrupt treatment until resolves to grade 1 or lower, resume sorafenib with the dose reduced by 1 dose level.</p>
<p style="text-indent:0em;">If no resolution after 30 days of treatment interruption, discontinue treatment unless patient is deriving clinical benefit. If more than 2 dose reductions are necessary, permanently discontinue sorafenib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue sorafenib.</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;">Hypertension</p></td>
<td align="center" colspan="2">
<p style="text-indent:0em;">If indicated, initiate appropriate antihypertensive therapy<sup>a</sup> to reduce the risk for cardiovascular complications<sup>b</sup>.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 2 symptomatic/persistent or grade 2 symptomatic increase by &gt;20 mm Hg (diastolic) or &gt;140/90 mm Hg if previously within normal limits or grade 3</p></td>
<td align="center">
<p style="text-indent:0em;">Interrupt sorafenib treatment (and manage with antihypertensive therapy) until symptoms resolve and diastolic BP is &lt;90 mm Hg, then resume with the dose reduced by 1 dose level. If needed, reduce an additional dose level. If more than 2 dose reductions are necessary, permanently discontinue sorafenib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue sorafenib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">QT prolongation</p></td>
<td align="center">
<p style="text-indent:0em;">QTc interval &gt;500 msec or ≥60 msec increase from baseline</p></td>
<td align="center">
<p style="text-indent:0em;">Interrupt treatment and correct electrolyte (magnesium potassium, calcium) abnormality. Use medical judgment before restarting.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">GI perforation</p></td>
<td align="center">
<p style="text-indent:0em;">Any grade</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue sorafenib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Hemorrhage</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 2 or higher requiring medical intervention</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue sorafenib.</p></td></tr>
<tr>
<td align="center" rowspan="5">
<p style="text-indent:0em;">Other nonhematologic toxicities</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 2</p></td>
<td align="center">
<p style="text-indent:0em;">Continue treatment with the dose reduced by 1 dose level.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3 (first occurrence)</p></td>
<td align="center">
<p style="text-indent:0em;">Interrupt treatment until resolves to grade 2 or less, then resume with the dose reduced by 1 dose level.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3 (no improvement within 7 days or second or third occurrence)</p></td>
<td align="center">
<p style="text-indent:0em;">Interrupt treatment until resolves to grade 2 or less, then resume with the dose reduced by 2 dose levels.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3 (fourth occurrence)</p></td>
<td align="center">
<p style="text-indent:0em;">Interrupt treatment until resolves to grade 2 or less, then resume with the dose reduced by 2 dose levels (for hepatocellular or renal cell carcinomas) or by 3 levels (for differentiated thyroid carcinoma).</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue sorafenib.</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Sorafenib Dosage Modifications for Dermatologic Toxicities</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;">Dermatologic toxicity grade</p></th>
<th align="center" rowspan="2">
<p style="text-indent:0em;">Occurrence</p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;">Sorafenib dosage modification<sup class="footnote-number">a</sup></p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">Hepatocellular and renal cell carcinoma</p></th>
<th align="center">
<p style="text-indent:0em;">Differentiated thyroid carcinoma</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="4" valign="middle">
<p style="text-indent:0em;text-align:left;">
<b>
<sup>a</sup></b>Following improvement of grade 2 or 3 dermatologic toxicity to grade 0 to 1 after at least 28 days of a reduced dose, the sorafenib dose may be increased 1 dose level from the reduced dose. Approximately 50% of patients requiring a dose reduction for dermatologic toxicity are expected to meet these criteria for resumption of the higher dose and roughly 50% of patients resuming the previous dose are expected to tolerate the higher dose (that is, maintain the higher dose level without recurrent grade 2 or higher dermatologic toxicity).</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;">Grade 2: Painful erythema and swelling of the hands or feet and/or discomfort affecting normal activities</p></td>
<td align="center">
<p style="text-indent:0em;">First occurrence</p></td>
<td align="center">
<p style="text-indent:0em;">Continue sorafenib treatment and consider topical therapy for symptomatic relief. If no improvement within 7 days, see below.</p></td>
<td align="center">
<p style="text-indent:0em;">Decrease dose to 600 mg daily. If no improvement within 7 days, see below.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">No improvement within 7 days or second or third occurrence</p></td>
<td align="center">
<p style="text-indent:0em;">Interrupt sorafenib treatment until resolved or improved to grade 0 to 1. When resuming treatment, decrease dose by 1 dose level.</p></td>
<td align="center">
<p style="text-indent:0em;">Interrupt sorafenib treatment until completely resolved or improved to grade 1. When resuming treatment, decrease dose by 1 dose level for second occurrence and by 2 dose levels for third occurrence.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Fourth occurrence</p></td>
<td align="center" colspan="2">
<p style="text-indent:0em;">Discontinue sorafenib treatment.</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;">Grade 3: Moist desquamation, ulceration, blistering, or severe pain of the hands or feet, resulting in inability to work or perform activities of daily living</p></td>
<td align="center">
<p style="text-indent:0em;">First occurrence</p></td>
<td align="center">
<p style="text-indent:0em;">Interrupt sorafenib treatment until resolved or improved to grade 0 to 1. When resuming treatment, decrease dose by 1 dose level.</p></td>
<td align="center">
<p style="text-indent:0em;">Interrupt sorafenib treatment until completely resolved or improved to grade 1. When resuming treatment, decrease dose by 1 dose level.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Second occurrence</p></td>
<td align="center">
<p style="text-indent:0em;">Interrupt sorafenib treatment until resolved or improved to grade 0 to 1. When resuming treatment, decrease dose by 1 dose level.</p></td>
<td align="center">
<p style="text-indent:0em;">Interrupt sorafenib treatment until completely resolved or improved to grade 1. When resuming treatment, decrease dose by 2 dose levels.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Third occurrence</p></td>
<td align="center" colspan="2">
<p style="text-indent:0em;">Discontinue sorafenib treatment.</p></td></tr>
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;">Suspected Stevens-Johnson syndrome or toxic epidermal necrolysis</p></td>
<td align="center" colspan="2">
<p style="text-indent:0em;">Discontinue sorafenib treatment.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F2530072"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F2307898"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (9% to 41%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (14% to 67%), palmar-plantar erythrodysesthesia (21% to 69%), pruritus (14% to 20%), skin rash (including desquamation; 19% to 40%), xeroderma (10% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypoalbuminemia (59%), hypocalcemia (12% to 36%), hypophosphatemia (35% to 45%), increased amylase (30% to 34%), increased thyroid stimulating hormone level (&gt;0.5 mU/L: 41%), weight loss (10% to 49%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (11% to 31%), anorexia (16% to 29%), constipation (14% to 16%), decreased appetite (30%), diarrhea (43% to 68%), gastrointestinal hemorrhage, increased serum lipase (40% to 41%), nausea (21% to 24%), stomatitis (24%; grades 3/4: 2%), vomiting (11% to 16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, hemorrhage (15% to 17%; grades 3/4: 2%), increased INR (42%; grades 3/4: 4%), leukopenia, lymphocytopenia (23% to 47%; grades 3/4: 13%), neutropenia (18%; grades 3/4: 5%), thrombocytopenia (12% to 46%; grades 3/4: 1% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic insufficiency (11%), increased serum alanine aminotransferase (59%), increased serum aspartate aminotransferase (54%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (37% to 46%), headache (10% to 17%), mouth pain (14%), pain (including tumor pain), peripheral sensory neuropathy (13%), voice disorder (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (12%), limb pain (15%), ostealgia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (14%), respiratory tract hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac failure (2%), flushing, ischemic heart disease (including myocardial infarction: 2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris, erythema of skin (10%), exfoliative dermatitis, folliculitis, hyperkeratosis (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypokalemia (5% to 10%), hyponatremia, hypothyroidism</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia (6%), dyspepsia, dysphagia, gastroesophageal reflux disease, glossalgia, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Erectile dysfunction, proteinuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Squamous cell carcinoma of skin (3%; grades 3/4: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (10%), muscle spasm (10%), myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal failure syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis (7%), flu-like symptoms, rhinorrhea</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia, hypertensive crisis, prolonged QT interval on ECG, thromboembolism, transient ischemic attacks</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Eczema, erythema multiforme</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration, gynecomastia, hyperthyroidism</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholangitis, cholecystitis, gastritis, gastrointestinal perforation, pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Nephrotic syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure, hepatic injury, increased serum alkaline phosphatase (transient), increased serum bilirubin, jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebral hemorrhage, reversible posterior leukoencephalopathy syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial pulmonary disease (acute respiratory distress, interstitial pneumonitis, pneumonitis, radiation pneumonitis)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Hepatic: Hepatitis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombotic microangiopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Osteonecrosis of the jaw, rhabdomyolysis</p></div>
<div class="block coi drugH1Div" id="F2307894"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Known severe hypersensitivity to sorafenib or any component of the formulation; use in combination with carboplatin and paclitaxel in patients with squamous cell lung cancer.</p></div>
<div class="block war drugH1Div" id="F2307895"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding: Increased risk of bleeding may occur; consider permanently discontinuing sorafenib with serious bleeding events (eg, requires medical intervention). Fatal bleeding events have been reported. Thyroid cancer patients with tracheal, bronchial, and esophageal infiltration should be treated with local therapy prior to administering sorafenib due to the potential bleeding risk.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular events: Sorafenib may cause cardiac ischemia or infarction; heart failure has been reported in multiple clinical studies. Depending on the severity, cardiovascular events may require treatment interruption, dose reduction, and/or discontinuation. Patients with unstable coronary artery disease or recent myocardial infarction were excluded from some studies. In a scientific statement from the American Heart Association, sorafenib has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: minor) (AHA [Page 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic toxicity: Hand-foot skin reaction and rash (generally grades 1 or 2) are the most common drug-related adverse events and typically appear within the first 6 weeks of sorafenib treatment. Dermatologic toxicity is usually managed with topical treatment, treatment delays, dose reductions, and/or (in severe or persistent cases), permanent discontinuation. The risk for hand-foot skin reaction increased with cumulative doses of sorafenib; in addition, the incidence of hand-foot skin reaction is increased in patients treated with sorafenib plus bevacizumab in comparison to those treated with sorafenib monotherapy (Azad 2009). Severe dermatologic toxicities, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported; may be life-threatening. Discontinue sorafenib for suspected SJS or TEN.</p>
<p style="text-indent:-2em;margin-left:6em;">The following treatments may be used to manage hand-foot skin reaction in addition to the recommended dosage modifications (Lacouture 2008): Prior to treatment initiation, a pedicure is recommended to remove hyperkeratotic areas/calluses, which may predispose to HFSR; avoid vigorous exercise/activities which may stress hands or feet. During therapy, patients should reduce exposure to hot water (may exacerbate hand-foot symptoms); avoid constrictive footwear and excessive skin friction. Patients may also wear thick cotton gloves or socks and should wear shoes with padded insoles. Grade 1 HFSR may be relieved with moisturizing creams, cotton gloves and socks (at night) and/or keratolytic creams such as urea (20% to 40%) or salicylic acid (6%). Apply topical steroid (eg, clobetasol ointment) twice daily to erythematous areas of grade 2 HFSR; topical anesthetics (eg, lidocaine 2%) and then systemic analgesics (if appropriate) may be used for pain control. Resolution of acute erythema may result in keratotic areas which may be softened with keratolytic agents.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI perforation: GI perforation has been reported (rare); monitor patients for signs/symptoms (abdominal pain, constipation, or vomiting); permanently discontinue sorafenib treatment if GI perforation occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Sorafenib-induced hepatitis (characterized by a hepatocellular pattern of liver damage with significant increases of transaminases) may result in hepatic failure and death. Bilirubin elevations and INR increases may also occur. Severe drug-induced liver injury (transaminase elevations &gt;20 times ULN or with significant clinical sequelae [eg, elevated INR, ascites, transplantation or fatality]) occurred rarely. Monitor LFTs regularly. Discontinue sorafenib if significantly increased transaminases occur without alternative explanation (eg, viral hepatitis, progressing underlying malignancy).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertension: Sorafenib may cause hypertension (generally mild to moderate), especially in the early course of sorafenib treatment. Monitor BP weekly during first 6 weeks of treatment; thereafter, monitor and manage as appropriate. Consider discontinuing (temporary or permanent) in patients who develop severe or persistent hypertension while on appropriate antihypertensive therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• QT prolongation: QT prolongation has been observed with sorafenib; may increase the risk for ventricular arrhythmia. Avoid sorafenib in patients with congenital long QT syndrome. Monitor electrolytes and ECG in patients with heart failure, bradyarrhythmias, and concurrent medications know to prolong the QT interval. Correct electrolyte (calcium, magnesium, potassium) imbalances. Interrupt treatment for QTc interval &gt;500 msec or for ≥60 msec increase from baseline.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid impairment: Sorafenib impairs exogenous thyroid suppression. TSH level elevations were commonly observed in the thyroid carcinoma study; monitor TSH levels monthly and as clinically necessary, and adjust thyroid replacement as needed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Wound healing complications: Vascular endothelial growth factor receptor inhibitors are associated with impaired wound healing; therefore, sorafenib may affect wound healing. Withhold sorafenib treatment for at least 10 days prior to elective surgery; do not administer sorafenib for at least 2 weeks following major surgery and until adequate wound healing. The safety of resuming sorafenib treatment after resolution of wound healing complications has not been established.</p></div>
<div class="block foc drugH1Div" id="F2322564"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NexAVAR: 200 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg</p></div>
<div class="block geq drugH1Div" id="F2307885"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16322891"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (NexAVAR Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $255.13</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (SORAfenib Tosylate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $210.83 - $216.74</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868746"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NexAVAR: 200 mg</p></div>
<div class="block accres drugH1Div" id="F22875139"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Available from specialty pharmacies. Further information may be obtained at 1-866-639-2827 or www.nexavar-us.com.</p></div>
<div class="block adm drugH1Div" id="F2309013"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer without food (at least 1 hour before or 2 hours after a meal).</p></div>
<div class="block hazard drugH1Div" id="F49132822"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F2307889"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatocellular carcinoma:</b> Treatment of unresectable hepatocellular carcinoma (HCC).</p>
<p style="text-indent:-2em;margin-left:4em;">According to guidelines from the American Society of Clinical Oncology for systemic therapy for advanced HCC, sorafenib is a first-line option for select patients with advanced HCC with Child Pugh class A hepatic impairment, performance status of 0 or 1, and with contraindications to atezolizumab and/or bevacizumab therapy. Sorafenib is a second-line therapy option in patients who received first-line therapy with atezolizumab and bevacizumab (ASCO [Gordan 2020]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal cell carcinoma, advanced:</b> Treatment of advanced renal cell carcinoma (RCC).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid carcinoma, differentiated:</b> Treatment of locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (refractory to radioactive iodine treatment).</p></div>
<div class="block off-label drugH1Div" id="F25471364"><span class="drugH1">Use: Off-Label: Adult</span><p>Angiosarcoma (recurrent or metastatic); Gastrointestinal stromal tumor (resistant or refractory)</p></div>
<div class="block mst drugH1Div" id="F3402005"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">NexAVAR may be confused with NexIUM.</p>
<p style="text-indent:-2em;margin-left:4em;">SORAfenib may be confused with axitinib, gefitinib, imatinib, lenvatinib, regorafenib, selumetinib, sonidegib, SUNItinib, tivozanib, vandetanib, vemurafenib.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F2309007"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major), UGT1A9; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> BSEP/ABCB11, UGT1A1</p></div>
<div class="block dri drugH1Div" id="F2309006"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: May enhance the hepatotoxic effect of SORAfenib. SORAfenib may increase the serum concentration of Acetaminophen. Management: Avoid coadministration of acetaminophen and sorafenib if possible. If coadministration is unavoidable, monitor for signs/symptoms of hepatotoxicity, particularly in patients with greater acetaminophen exposure.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: Hypertension-Associated Agents may enhance the hypertensive effect of Androgens. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belinostat: UGT1A1 Inhibitors may increase the serum concentration of Belinostat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bevacizumab: May enhance the adverse/toxic effect of SORAfenib. Specifically, the risk for hand-foot skin reaction may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: Angiogenesis Inhibitors (Systemic) may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Specifically, the risk for osteonecrosis of the jaw may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CARBOplatin: SORAfenib may enhance the adverse/toxic effect of CARBOplatin. CARBOplatin may increase the serum concentration of SORAfenib.  Management: Concurrent sorafenib with carboplatin and paclitaxel in patients with squamous cell lung cancer is contraindicated.  Use in other settings is not specifically contraindicated but should be approached with added caution.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholic Acid: BSEP/ABCB11 Inhibitors may decrease the excretion of Cholic Acid.  Management: Avoid the use of bile salt efflux pump inhibitors with cholic acid.  If such a combination cannot be avoided, monitor serum transaminases (eg, AST, ALT) and bilirubin closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of SORAfenib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of SORAfenib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dacarbazine: SORAfenib may enhance the adverse/toxic effect of Dacarbazine. SORAfenib may increase serum concentrations of the active metabolite(s) of Dacarbazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOCEtaxel: SORAfenib may increase the serum concentration of DOCEtaxel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">GlyBURIDE: SORAfenib may enhance the hypoglycemic effect of GlyBURIDE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May decrease the absorption of SORAfenib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Irinotecan Products: UGT1A1 Inhibitors may increase serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, concentrations of SN-38 may be increased. UGT1A1 Inhibitors may increase the serum concentration of Irinotecan Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neomycin (Systemic): May decrease the serum concentration of SORAfenib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obeticholic Acid: BSEP/ABCB11 Inhibitors may increase serum concentrations of the active metabolite(s) of Obeticholic Acid.  Management: Avoid concomitant use of obeticholic acid and bile salt efflux pump (BSEP) inhibitors if possible. If concomitant therapy is necessary, monitor patients for elevated liver transaminases and elevated bilirubin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Conventional): SORAfenib may enhance the adverse/toxic effect of PACLitaxel (Conventional).  Management: Concurrent sorafenib with carboplatin and paclitaxel in patients with squamous cell lung cancer is contraindicated.  Use in other settings is not specifically contraindicated but should be approached with added caution.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Protein Bound): SORAfenib may enhance the adverse/toxic effect of PACLitaxel (Protein Bound).  Management: Concurrent sorafenib with carboplatin and paclitaxel in patients with squamous cell lung cancer is contraindicated. Use in other settings is not specifically contraindicated but should be approached with added caution.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: SORAfenib may enhance the hepatotoxic effect of Propacetamol. SORAfenib may increase serum concentrations of the active metabolite(s) of Propacetamol. Specifically, acetaminophen exposure may be increased.  Management: Consider less frequent and/or lower daily doses of propacetamol in patients who are also taking sorafenib. Monitor for liver toxicity, particularly with higher propacetamol doses.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sacituzumab Govitecan: UGT1A1 Inhibitors may increase serum concentrations of the active metabolite(s) of Sacituzumab Govitecan. Specifically, concentrations of SN-38 may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: May enhance the hypertensive effect of Hypertension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: BSEP/ABCB11 Inhibitors may enhance the adverse/toxic effect of Taurursodiol. Specifically, the risk for liver dysfunction may be increased.  Management: Avoid coadministration of sodium phenylbutyrate and taurursodiol with BSEP inhibitors when possible. If concomitant use is necessary, monitoring of serum transaminases and bilirubin is recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Warfarin: SORAfenib may enhance the anticoagulant effect of Warfarin. SORAfenib may increase the serum concentration of Warfarin. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F2309009"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Bioavailability is decreased 29% with a high-fat meal containing 900 calories, 50% from fat (bioavailability is similar to fasting state when administered with a moderate-fat meal). Management: Administer without food, at least 1 hour before or 2 hours after a meal.</p></div>
<div class="block rep_considerations drugH1Div" id="F52434106"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status in females of reproductive potential prior to initiating sorafenib treatment. Females of reproductive potential should use effective contraception during treatment and for 6 months after the final sorafenib dose. Males with female partners of reproductive potential should use effective contraception during treatment and for 3 months after the last sorafenib dose.</p></div>
<div class="block pri drugH1Div" id="F2307891"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Information related to sorafenib use in pregnancy is limited (Mahdi 2018). Based on the mechanism of action and findings from animal reproduction studies, in utero exposure to sorafenib may cause fetal harm. Sorafenib inhibits angiogenesis, which is a critical component of fetal development.</p></div>
<div class="block brc drugH1Div" id="F5531300"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if sorafenib is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends discontinuing breastfeeding during sorafenib treatment and for 2 weeks after the final sorafenib dose.</p></div>
<div class="block mop drugH1Div" id="F2322559"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CBC with differential, electrolytes (magnesium, potassium, calcium), phosphorus, lipase and amylase levels; LFTs. Evaluate pregnancy status prior to treatment initiation (in females of reproductive potential). Monitor BP (baseline, weekly for the first 6 weeks, then as indicated). Monitor ECG in patients at risk for prolonged QT interval. Monitor for signs/symptoms of bleeding, GI perforation, hand-foot skin reaction and other dermatologic toxicities, heart failure, and/or impaired wound healing. Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid function testing:</p>
<p style="text-indent:-2em;margin-left:4em;">Patients with differentiated thyroid cancer: Monitor TSH monthly.</p>
<p style="text-indent:-2em;margin-left:4em;">Patients with RCC and HCC (Hamnvik 2011):</p>
<p style="text-indent:-2em;margin-left:6em;">Preexisting levothyroxine therapy: Obtain baseline TSH levels, then monitor every 4 weeks until levels and levothyroxine dose are stable, then monitor every 2 months.</p>
<p style="text-indent:-2em;margin-left:6em;">Without preexisting thyroid hormone replacement: TSH at baseline, then every 4 weeks for 4 months, then every 2 to 3 months.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Additional cardiovascular monitoring:</i> Comprehensive assessment prior to treatment, including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking (ASCO [Armenian 2017]; ESC [Lyon 2022]). BP at each clinical visit (as well as daily home monitoring for first cycle, after dose increases, and every 2 to 3 weeks thereafter); ECG and QTc assessment in patients at moderate- or high-risk of QTc prolongation (assess QTc monthly during the first 3 months and every 3 to 6 months thereafter); baseline echocardiography in high- and very high-risk patients (repeat every 3 months during the first year and every 6 to 12 months thereafter); consider baseline echocardiography in low- and moderate-risk patients (consider repeating every 4 months during the first year for moderate-risk patients and every 6 to 12 months thereafter) (ESC [Lyon 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F2322543"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Sorafenib is a multikinase inhibitor that inhibits tumor growth and angiogenesis by inhibiting intracellular Raf kinases (CRAF, BRAF, and mutant BRAF), and cell surface kinase receptors (VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-beta, cKIT, FLT-3, RET, and RET/PTC)</p></div>
<div class="block phk drugH1Div" id="F2322546"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 99.5%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic, via CYP3A4 (primarily oxidated to the pyridine N-oxide; active, minor) and UGT1A9 (glucuronidation).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 38% to 49%; reduced by 29% when administered with a high-fat (900 calories; 50% from fat) meal.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 25 to 48 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: ~3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (77%, 51% of dose as unchanged drug); urine (19%, as metabolites).</p></div>
<div class="block phksp drugH1Div" id="F51221462"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Race/ethnicity: Mean AUC in Asians is 30% lower than in white patients.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58844778"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Nexavar</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorafenib-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Atkins.1">
<a name="Atkins.1"></a>Atkins MB. Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 23, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19228742">
<a name="19228742"></a>Azad NS, Aragon-Ching JB, Dahut WL, et al, “Hand-Foot Skin Reaction Increases With Cumulative Sorafenib Dose and With Combination Anti-Vascular Endothelial Growth Factor Therapy,” <i>Clin Cancer Res</i>, 2009, 15(4):1411-16.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorafenib-drug-information/abstract-text/19228742/pubmed" id="19228742" target="_blank">19228742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24768112">
<a name="24768112"></a>Brose MS, Nutting CM, Jarzab B, et al; DECISION investigators. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319-328. doi: 10.1016/S0140-6736(14)60421-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorafenib-drug-information/abstract-text/24768112/pubmed" id="24768112" target="_blank">24768112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19451442">
<a name="19451442"></a>Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. <i>J Clin Oncol</i>. 2009;27(20):3312-3318.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorafenib-drug-information/abstract-text/19451442/pubmed" id="19451442" target="_blank">19451442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17215530">
<a name="17215530"></a>Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. <i>N Engl J Med</i>. 2007;356(2):125-134.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorafenib-drug-information/abstract-text/17215530/pubmed" id="17215530" target="_blank">17215530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33197225">
<a name="33197225"></a>Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. <i>J Clin Oncol</i>. 2020;38(36):4317-4345. doi:10.1200/JCO.20.02672<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorafenib-drug-information/abstract-text/33197225/pubmed" id="33197225" target="_blank">33197225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22010182">
<a name="22010182"></a>Hamnvik OP, Larsen PR, and Marqusee E, “Thyroid Dysfunction From Antineoplastic Agents,” <i>J Natl Cancer Inst</i>, 2011, 103(21):1572-87.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorafenib-drug-information/abstract-text/22010182/pubmed" id="22010182" target="_blank">22010182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorafenib-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kindler.2018">
<a name="Kindler.2018"></a>Kindler H, Campbell NP, Wroblewski K, et al. Final results of a University of Chicago phase II consortium trial of sorafenib (SOR) in patients (pts) with imatinib (IM)- and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST) (abstract). Data presented at the 2011 ASCO GI Cancers Symposium, January 20-22, San Francisco, CA. Abstract available online at https://meetinglibrary.asco.org/record/63320/abstract. Accessed December 14, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18779536">
<a name="18779536"></a>Lacouture ME, Wu S, Robert C, et al, “Evolving Strategies for the Management of Hand-Foot Skin Reaction Associated With the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib,” <i>Oncologist</i>, 2008, 13(9):1001-11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorafenib-drug-information/abstract-text/18779536/pubmed" id="18779536" target="_blank">18779536</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21275495">
<a name="21275495"></a>Lam MS. Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs. <i>Pharmacotherapy</i>. 2011;31(2):164-192. doi:10.1592/phco.31.2.164<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorafenib-drug-information/abstract-text/21275495/pubmed" id="21275495" target="_blank">21275495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18650514">
<a name="18650514"></a>Llovet J Ricci S, Mazzaferro V, et al, “Sorafenib in Advanced Hepatocellular Carcinoma,” <i>N Engl J Med,</i> 2008 Jul 24;359(4):378-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorafenib-drug-information/abstract-text/18650514/pubmed" id="18650514" target="_blank">18650514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J</i>. 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorafenib-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27766617">
<a name="27766617"></a>Mahdi AJ, Gosrani D, Chakraborty M, et al. Successful molecular targeted treatment of AML in pregnancy with azacitidine and sorafenib with no adverse fetal outcomes. <i>Br J Haematol</i>. 2018;180(4):603-604. doi:10.1111/bjh.14417<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorafenib-drug-information/abstract-text/27766617/pubmed" id="27766617" target="_blank">27766617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19451436">
<a name="19451436"></a>Maki RG, D'Adamo DR, Keohan ML, et al, “Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas,” <i>J Clin Oncol</i>, 2009, 27(19):3133-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorafenib-drug-information/abstract-text/19451436/pubmed" id="19451436" target="_blank">19451436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19255312">
<a name="19255312"></a>Miller AA, Murry DJ, Owzar K, et al, “Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301,” <i>J Clin Oncol</i>, 2009, 27(11):1800-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorafenib-drug-information/abstract-text/19255312/pubmed" id="19255312" target="_blank">19255312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23140824">
<a name="23140824"></a>Montemurro M, Gelderblom H, Bitz U, et al. Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis. <i>Eur J Cancer</i>. 2013;49(5):1027-1031. doi: 10.1016/j.ejca.2012.10.009.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorafenib-drug-information/abstract-text/23140824/pubmed" id="23140824" target="_blank">23140824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nexavar.1">
<a name="Nexavar.1"></a>Nexavar (sorafenib) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorafenib-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22270258">
<a name="22270258"></a>Park SH, Ryu MH, Ryoo BY, et al. Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. <i>Invest New Drugs</i>. 2012;30(6):2377-2383. doi: 10.1007/s10637-012-9795-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorafenib-drug-information/abstract-text/22270258/pubmed" id="22270258" target="_blank">22270258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30729654">
<a name="30729654"></a>Paw Cho Sing E, Robinson PD, Flank J, et al. Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline. <i>Pediatr Blood Cancer</i>. 2019;66(5):e27646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorafenib-drug-information/abstract-text/30729654/pubmed" id="30729654" target="_blank">30729654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28872925">
<a name="28872925"></a>Reiss KA, Yu S, Mamtani R, et al. Starting dose of sorafenib for the treatment of hepatocellular carcinoma: a retrospective, multi-institutional study. <i>J Clin Oncol</i>. 2017;35(31):3575-3581. doi: 10.1200/JCO.2017.73.8245.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorafenib-drug-information/abstract-text/28872925/pubmed" id="28872925" target="_blank">28872925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20212250">
<a name="20212250"></a>Scagliotti G, Novello S, von Pawel J, et al, “Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non-Small-Cell Lung Cancer,” <i>J Clin Oncol</i>, 2010, 38(11):1835-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorafenib-drug-information/abstract-text/20212250/pubmed" id="20212250" target="_blank">20212250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19107763">
<a name="19107763"></a>Yau T, Chan P, Ng KK, et al, “Phase 2 Open-Label Study of Single Agent Sorafenib in Treating Advanced Hepatocellular Carcinoma in a Hepatitis B–Endemic Asian Population,” <i>Cancer</i>, 2009, 115(2):428-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorafenib-drug-information/abstract-text/19107763/pubmed" id="19107763" target="_blank">19107763</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10277 Version 315.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
